China Thrombosis Therapeutics Market Size & Growth Rate
According to 6Wresearch internal database and industry insights, the China Thrombosis Therapeutics Market was valued at USD 1.77 billion in 2025 and is projected to reach USD 2.64 billion by 2032, growing at a CAGR of approximately 5.9% during 2026–2032.
China Thrombosis Therapeutics Market Highlights
| Report Metric | Details |
| Report Name | China Thrombosis Therapeutics Market |
| Market Size 2025 | USD 1.77 billion |
| Market Size 2032 | USD 2.64 billion |
| Absolute Growth 2025–2032 | USD 0.87 billion |
| CAGR 2026–2032 | 5.9% |
| Peak Annual Growth | 7.9% in 2028 |
| Forecast Period | 2026–2032 |
| Historical Data | 2022–2025 |
| Base Year | 2025 |
| Leading Therapeutic Class, 2025 | Anticoagulants (42% share) |
| Leading Mechanism of Action, 2025 | Inhibit Clotting Factors (52% share) |
| Leading Administration Route, 2025 | Oral (57% share) |
| Leading End User, 2025 | General Hospitals (38% share) |
| Fastest-Growing Therapeutic Class | NOACs (8.1% CAGR) |
| Fastest-Growing Mechanism of Action | Target Factor Xa/IIa (8.2% CAGR) |
| Fastest-Growing End User | Stroke Units (8.2% CAGR) |
| Growing Sector | Cardiovascular Care |
| Key End Users | General Hospitals, Stroke Units, ICUs, Cardiologists |
China Thrombosis Therapeutics Market Year-wise Growth Rate and Key Drivers (2022–2032)
This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.
Each row of the following table gives one year's estimated growth and the event or demand shift that explains it.
| Year | Estimated Annual Growth (%) | Market Rationale |
| 2022 | 4.2 | The market experienced steady growth due to rising hospital admissions for cardiovascular diseases, with over 10 million cases reported. |
| 2023 | 3.8 | Growth slowed as healthcare systems adjusted to the increasing prevalence of thrombotic disorders, particularly in urban areas. |
| 2024 | 5.6 | Demand surged as hospitals expanded their thrombosis treatment capabilities, driven by the 2021 Cardiovascular Disease Prevention Plan. |
| 2025 | 6.4 | Increased awareness and guidelines from the Chinese Society of Cardiology led to stronger market performance. |
| 2026 | 4.1 | The market is expected to grow at a slower rate as the Chinese FDA's approval processes stabilise following recent peaks in demand. |
| 2027 | 5.3 | A rise in the prevalence of thrombotic disorders is projected to drive demand higher, particularly among general hospitals. |
| 2028 | 7.9 | The market is expected to peak as new therapies gain widespread acceptance in hospitals across major urban centres. |
| 2029 | 7.2 | Growth is projected to slow due to adjustments following the peak year, affecting purchasing patterns. |
| 2030 | 4.4 | The market will continue to grow as healthcare providers focus on effective treatments for thrombotic events. |
| 2031 | 7.6 | Demand is expected to rise again with the introduction of new clinical guidelines for thrombosis management. |
| 2032 | 4.7 | Growth is projected to slow as the market stabilises after rapid expansions in treatment options. |
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
China Thrombosis Therapeutics Market Synopsis
Thrombosis Therapeutics in China includes medications designed to prevent and treat blood clots, such as anticoagulants, antiplatelet drugs, and fibrinolytic agents. These treatments are primarily used for conditions like deep vein thrombosis and pulmonary embolism. The China Thrombosis Therapeutics Market is growing due to the increasing incidence of thrombotic disorders and a rise in hospital admissions. In 2022, more than 10 million hospital admissions for cardiovascular diseases underscored the urgent need for effective treatment options. Initiatives like the 2021 Cardiovascular Disease Prevention Plan are further promoting the adoption of these therapies.
Market Dynamics Impact Analysis (2026–2032)
| Factor | Type | Impact | Primary Segment Affected |
| Rising incidence of thrombotic disorders among the aging population | Driver | High | Anticoagulants |
| Increased hospital admissions for cardiovascular diseases | Driver | High | General Hospitals |
| Growing demand for innovative treatment solutions | Opportunity | High | NOACs |
| Expansion of specialized stroke units in urban centres | Opportunity | Medium | Stroke Units |
| Challenges in regulatory approval processes for new therapies | Restraint | High | Fibrinolytic Agents |
| Limited awareness among healthcare professionals regarding new treatments | Restraint | Medium | Antiplatelet Drugs |
| High costs associated with advanced thrombosis therapies | Challenge | High | General Hospitals |
| Inconsistent access to thrombosis therapeutics in rural areas | Challenge | Medium | ICUs |
Evaluation of Drivers in China Thrombosis Therapeutics Market (2026–2032)
The table below links each growth driver to the segment it affects and the evidence for it.
| Drivers | Primary Segment Affected | Why It Matters (Evidence) |
| Increasing prevalence of atrial fibrillation driving anticoagulant use | Anticoagulants | The estimated 5 million cases of atrial fibrillation in China boost demand for anticoagulants, as they are essential for managing this condition. |
| Rising hospital admissions for cardiovascular diseases | General Hospitals | Over 10 million hospital admissions in 2022 necessitate effective thrombosis therapies, leading to increased purchases by general hospitals. |
| Growing preference for NOACs due to convenience and efficacy | NOACs | Clinical guidelines recommend NOACs for non-valvular atrial fibrillation, prompting hospitals to stock these medications. |
| Expansion of stroke units in major urban centres | Stroke Units | Urban centres like Beijing and Shanghai are enhancing stroke care, increasing the demand for thrombosis therapeutics. |
| Investment in cardiovascular disease research | Fibrinolytic Agents | The 500 million CNY allocated for research in 2023 supports the development of new fibrinolytic agents. |
The Thrombosis Therapeutics market in China is expanding as the prevalence of atrial fibrillation rises, increasing demand for anticoagulants. With an estimated 5 million cases, hospitals are purchasing more anticoagulants to manage this condition effectively. Over 10 million hospital admissions for cardiovascular diseases in 2022 have led to a notable uptick in demand for thrombosis therapies. Guidelines promoting NOACs for non-valvular atrial fibrillation are encouraging healthcare providers to stock these medications. The establishment of specialized stroke units in urban centres like Beijing is also driving the need for effective thrombosis treatment options.
Evaluation of Restraints in China Thrombosis Therapeutics Market
Below mentioned are some major restraints and their influence on market dynamics.
| Market Restraint | Primary Segment Affected | Why It Matters (Evidence) |
| Regulatory hurdles delaying new product approvals | Fibrinolytic Agents | The Drug Registration Regulation updates in 2020 have not fully streamlined the approval process, causing delays for new fibrinolytic agents. |
| Limited awareness of thrombosis treatments among healthcare providers | Antiplatelet Drugs | Many healthcare professionals are not fully aware of the latest antiplatelet therapies, impacting their prescription rates. |
| High costs of advanced thrombosis therapeutics | General Hospitals | The high prices of advanced thrombosis treatments can strain hospital budgets, limiting their ability to purchase new therapies. |
| Inconsistent access to therapies in rural areas | ICUs | Patients in rural regions often face challenges in accessing essential thrombosis treatments, affecting overall market growth. |
| Shortage of trained personnel in specialized stroke units | Stroke Units | The lack of trained staff in stroke units can hinder the effective use of thrombosis therapeutics. |
China Thrombosis Therapeutics Market Challenges
In China, the over 10 million hospital admissions for cardiovascular diseases highlight the pressing need for thrombosis therapeutics. Buyers in rural areas face challenges due to limited access to advanced anticoagulants, which can delay treatment and potentially worsen patient outcomes. Supply issues stem from the stringent regulatory approval processes mandated by the Chinese FDA, prolonging the time for new therapies to reach hospitals and impacting patient care. Price competition among suppliers may lead to diminished quality of therapeutics, jeopardising patient safety and increasing the risk of complications for healthcare providers.
Trends in the China Thrombosis Therapeutics Market
Buyers and suppliers in the China Thrombosis Therapeutics Market are adjusting to the following trends.
- Shift towards NOACs in Clinical Guidelines: The Chinese Society of Cardiology's 2022 guidelines increasingly recommend NOACs for patients with non-valvular atrial fibrillation, reflecting a shift in treatment preferences. This change is likely to drive demand, as hospitals adapt to new protocols.
- Growing Focus on Cardiovascular Health Promotion: The 2022 Cardiovascular Health Promotion Program aims to reduce thrombotic events nationwide, encouraging healthcare facilities to adopt preventive measures. This initiative is projected to increase the market for thrombosis therapeutics by raising awareness.
- Expansion of Stroke Units in Urban Areas: Major urban centres like Beijing have established specialized stroke units to improve patient outcomes. With over 200 units reported in 2023, this trend is expected to drive the demand for thrombosis treatments.
- Increased Funding for Cardiovascular Research: In 2023, the Chinese government allocated 300 million CNY for research on thrombosis treatment solutions. This funding is likely to accelerate the development of new therapies, boosting market growth.
Investment Opportunities in the China Thrombosis Therapeutics Market
Some of the investment opportunities in the China Thrombosis Therapeutics Market are mentioned below.
- Growing Need for Advanced Thrombosis Treatments: With the rising incidence of thrombotic disorders, there is a strong opportunity to invest in advanced thrombosis therapies. Hospitals across China are seeking improved solutions to manage these conditions, particularly in urban areas.
- Investment in Stroke Unit Development: The establishment of new stroke units offers an opportunity for suppliers to provide thrombosis therapeutics. Major urban centres are expanding these units, creating demand for effective treatment options.
- Market Gap for Affordable Antiplatelet Drugs: The high costs of existing antiplatelet therapies reveal a market gap for more affordable options. Hospitals are in search of cost-effective solutions to manage post-myocardial infarction patients effectively.
- Expansion of Research and Development Facilities: The Chinese government's funding for cardiovascular disease research presents an opportunity for investment in R&D facilities. Collaborating with local healthcare providers can facilitate entry into the market.
Government Initiatives in the China Thrombosis Therapeutics Market
In 2023, the National Health Commission introduced new guidelines for the clinical use of NOACs, improving patient access to these therapies. This measure builds on the 2021 Cardiovascular Disease Prevention Plan, aimed at enhancing treatment options for thrombotic diseases. Together, these initiatives streamline the adoption of effective therapies and ensure better patient outcomes across China. The updated guidelines are expected to increase the availability of NOACs in hospitals nationwide, benefiting both producers and patients.
The Thrombosis Prevention and Control Action Plan implemented by the National Health Commission has raised awareness and treatment options for thrombotic diseases. This plan encourages healthcare providers to utilise thrombosis therapeutics effectively, ensuring that patients receive timely care. The Ministry of Health supports this initiative by funding educational programs for healthcare professionals, allocating 300 million CNY in 2023. This funding enables better training and resources for providers, improving the overall quality of care.
Future Insight of the China Thrombosis Therapeutics Market
By 2032, buyers and suppliers in the China thrombosis therapeutics market will experience notable changes driven by the 2021 Health China Initiative, which promotes advancements in treatment options. The increasing prevalence of thrombotic disorders will create a higher demand for effective therapies, leading to enhanced research and development. With 500 million CNY allocated for cardiovascular disease research, funding will facilitate advancements in treatment methodologies. Updated clinical guidelines from the Chinese Society of Cardiology will further improve management practices for thrombotic conditions.
Market Segmentation Analysis
The analysis below covers each segmentation, its leading category in 2025 and its fastest-growing category through 2032.
By Therapeutic Class – Anticoagulants Dominated, NOACs Expected to Grow Fastest
According to Vasudha, AM at 6Wresearch, Anticoagulants took a 42% share of therapeutic class in 2025, more than any other category. Anticoagulants hold the largest share in the China thrombosis therapeutics market due to their extensive use in hospitals for treating thrombotic disorders. With over 10 million hospital admissions for cardiovascular diseases in 2022, the demand for these medications remains high. NOACs are set to record the highest CAGR in this split, 8.1% over 2026–2032. NOACs are experiencing rapid growth as they are increasingly recommended under the 2021 Cardiovascular Disease Prevention Plan, reflecting a shift towards more convenient treatment options. The growing prevalence of atrial fibrillation, estimated at 5 million cases, further drives the adoption of NOACs. Suppliers should focus on expanding their NOAC offerings to meet the rising demand in China's healthcare system.
By Mechanism of Action – Inhibit Clotting Factors Dominated, Target Factor Xa/IIa Expected to Grow Fastest
In 2025, Inhibit Clotting Factors led the mechanism of action split with a 52% share. The Inhibit Clotting Factors segment commands the largest market share due to its fundamental role in anticoagulation therapy, which is vital for treating thrombotic conditions. This mechanism is widely adopted in healthcare facilities, ensuring consistent demand for thrombosis therapeutics. The quickest growth will come from Target Factor Xa/IIa, forecast to expand at a CAGR of 8.2% between 2026 and 2032. Target Factor Xa/IIa is witnessing the fastest growth as its targeted action in modern anticoagulants significantly improves treatment efficacy. As clinical guidelines increasingly recommend these therapies, their uptake is expected to surge. Suppliers should focus on promoting targeted therapies to enhance patient outcomes in thrombotic disorder management.
By Administration Route – Oral Dominated and Is Expected to Record the Fastest Growth
The largest administration route category in 2025 was Oral, with a 57% share of total revenue. The Oral administration route leads the market because many anticoagulants are available in this user-friendly form, making them easily accessible for patients. This preference is underscored by the average hospital stay of around 7 days for thrombotic events, indicating the need for manageable treatment options. The same category is also set to grow fastest, at a CAGR of 7.0% during 2026–2032. Oral remains the fastest-growing route, aligning with patient preferences for convenience and adherence to treatment regimens. The expanding availability of effective oral anticoagulants is set to further strengthen this trend. Suppliers should focus on developing oral formulations to meet the increasing demand from patients and healthcare providers.
By End User – General Hospitals Dominated, Stroke Units Expected to Grow Fastest
With a 38% revenue share in 2025, General Hospitals was the largest end user category. General Hospitals hold the largest market share as they provide extensive care for thrombotic disorders across various departments. The significant installed base of thrombosis therapeutic devices in these hospitals underscores their crucial role in patient treatment. Over 2026–2032, Stroke Units are expected to post the fastest growth, at a CAGR of 8.2%. Stroke Units are the fastest-growing end user segment, reflecting the establishment of specialised care facilities in major urban areas like Beijing and Shanghai. This growth is propelled by the rising incidence of thrombotic events necessitating immediate care. Suppliers should prioritise engagement with stroke units to align with the trend towards specialised care in thrombotic disorder treatment.
Key Attractiveness of the Report
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- China Thrombosis Therapeutics Market Outlook
- Market Size of China Thrombosis Therapeutics Market, 2025
- Forecast of China Thrombosis Therapeutics Market, 2032
- Historical Data and Forecast of China Thrombosis Therapeutics Revenues & Volume for the Period 2022 - 2032F
- China Thrombosis Therapeutics Market Trend Evolution
- China Thrombosis Therapeutics Market Drivers and Challenges
- China Thrombosis Therapeutics Price Trends
- China Thrombosis Therapeutics Porter's Five Forces
- China Thrombosis Therapeutics Industry Life Cycle
- Historical Data and Forecast of China Thrombosis Therapeutics Market Revenues & Volume By Therapeutic Class for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Therapeutics Market Revenues & Volume By Anticoagulants for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Therapeutics Market Revenues & Volume By Antiplatelet Drugs for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Therapeutics Market Revenues & Volume By Fibrinolytic Agents for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Therapeutics Market Revenues & Volume By NOACs for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Therapeutics Market Revenues & Volume By Mechanism of Action for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Therapeutics Market Revenues & Volume By Inhibit Clotting Factors for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Therapeutics Market Revenues & Volume By Block Platelet Aggregation for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Therapeutics Market Revenues & Volume By Dissolve Clots for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Therapeutics Market Revenues & Volume By Target Factor Xa/IIa for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Therapeutics Market Revenues & Volume By Administration Route for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Therapeutics Market Revenues & Volume By Oral/Injectable for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Therapeutics Market Revenues & Volume By Oral for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Therapeutics Market Revenues & Volume By IV for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Therapeutics Market Revenues & Volume By Oral for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Therapeutics Market Revenues & Volume By End User for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Therapeutics Market Revenues & Volume By Cardiologists for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Therapeutics Market Revenues & Volume By Stroke Units for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Therapeutics Market Revenues & Volume By ICUs for the Period 2022 - 2032F
- Historical Data and Forecast of China Thrombosis Therapeutics Market Revenues & Volume By General Hospitals for the Period 2022 - 2032F
- China Thrombosis Therapeutics Import Export Trade Statistics
- Market Opportunity Assessment By Therapeutic Class
- Market Opportunity Assessment By Mechanism of Action
- Market Opportunity Assessment By Administration Route
- Market Opportunity Assessment By End User
- China Thrombosis Therapeutics Top Companies Market Share
- China Thrombosis Therapeutics Competitive Benchmarking By Technical and Operational Parameters
- China Thrombosis Therapeutics Company Profiles
- China Thrombosis Therapeutics Key Strategic Recommendations
Market Covered
Segments analysed in this report are listed below.
By Therapeutic Class
- Anticoagulants
- Antiplatelet Drugs
- Fibrinolytic Agents
- NOACs
By Mechanism of Action
- Inhibit Clotting Factors
- Block Platelet Aggregation
- Dissolve Clots
- Target Factor Xa/IIa
By Administration Route
- Oral/Injectable
- Oral
- IV
By End User
- Cardiologists
- Stroke Units
- ICUs
- General Hospitals
